GlassScriptPhysician profile
Phillip W Bale
NPI 1376533992
$7,361.44
in general payments reported to CMS, 2019-2025
52 companies · $978 in 2025
The $978 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $567 · 2021: $912 · 2022: $1,115 · 2023: $1,330 · 2024: $1,226 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.58 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,027.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $640.40 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $492.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $470.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $461.59 | 2019-2025 | |
| Lilly USA, LLC | $383.89 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $317.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.14 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $247.44 | 2019-2023 | Spravato, Xarelto |
| Allergan, INC. | $237.81 | 2019-2020 | |
| Glaxosmithkline, LLC. | $213.25 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $212.41 | 2019-2024 | Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $191.82 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.54 | 2022-2025 | Caplyta |
| Dexcom, INC. | $154.24 | 2021-2025 | Dexcom G6 Transmitter |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Bale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.